IDDF2023-ABS-0099 Fibrosis-4 Index Predicts Adverse Cardiovascular Outcomes among Patients Comorbid with MAFLD and Coronary Heart Disease

Zhen Jin,Yupeng Liu,Wenyao Wang,Yi-Da Tang

DOI: https://doi.org/10.1136/gutjnl-2023-iddf.134

2023-01-01

Abstract:Background Comorbid metabolic (dysfunction)-associated fatty liver disease (MAFLD) and cardiovascular disease (CVD) are highly prevalent conditions. Liver fibrosis is related to adverse outcomes of liver disease and CVD. This study aims to investigate the association between liver fibrosis staged by Fibrosis-4 (FIB-4) index and adverse cardiovascular outcomes among patients comorbid with MAFLD and coronary heart disease (CHD). Methods 7802 consecutive patients comorbid with MAFLD and CHD were divided into two groups according to FIB-4<3.25 (mild liver fibrosis, n=7496) and FIB-4≥3.25 (advanced liver fibrosis, n=219). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCEs), including all-cause death, myocardial infarction (MI), stroke, stent thrombosis and target vessel revascularization (TVR). Results During the median 2.4-year follow-up, 631 MACCEs were recorded. Patients with FIB-4≥3.25 exhibited a significantly higher cumulative incidence of MACCEs (14.6% versus 8.4%), all-cause death (5.0% versus 1.1%), MI (4.6% versus 1.1%) and stent thrombosis (4.6% versus 0.8%) than those with FIB-4<3.25 (all p<0.05), but not stroke and TVR. The Kaplan-Meier analysis showed that patients with FIB-4≥3.25 had significantly lower event-free survival rates of MACCEs, all-cause death, MI and stent thrombosis (all p<0.05) but not stroke and TVR, compared to those with FIB-4<3.25 (IDDF2023-ABS-0099 Figure 1. The cumulative event-free survival analysis based on the FIB-4 index). Consistently, Cox proportional hazards regression analysis found patients with FIB-4≥3.25 had a significantly increased risk for MACCEs (HR 1.79, 95% confidential interval (CI) 1.26-2.56, p<0.05), all-cause death (HR 4.61, 95% CI 2.46-8.64, p<0.05), MI (HR 4.06, 95% CI 2.11-7.81, p<0.05) and stent thrombosis (HR 5.72, 95% CI 2.93-11.16, p<0.05). Liver fibrosis was identified as a potent prognostic factor in patients comorbid with MAFLD and CHD. Conclusions Advanced liver fibrosis staged by the FIB-4 index was associated with increased MACCEs, all-cause death, MI and stent thrombosis in patients comorbid with MAFLD and CHD.